Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Ustekinumab Devices in Healthy Participants
NCT04816513Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2021
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ustekinumab in plaque psoriasis, psoriatic arthritis (PsA), Crohn's disease and 1 more (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Serum Concentration and Area Under the Serum Concentration Versus Time Curve. Started Apr 2021; status: completed.
02
Drugs
ustekinumab
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04816513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04816513.